ScoreWhy is Interpace Biosciences, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 9.22% and Operating profit at 16.62% over the last 5 years
- The company has a negative book value of Rs 0.30 crore
2
Flat results in Mar 26
- NET SALES(HY) At USD 18.26 MM has Grown at -23.7%
- NET PROFIT(Q) At USD 0.83 MM has Fallen at -86.63%
- DEBTORS TURNOVER RATIO(HY) Lowest at 4.93 times
3
With ROE of -408.70%, it has a risky valuation with a -7.76 Price to Book Value
- Over the past year, while the stock has generated a return of 90.06%, its profits have fallen by -27.1%
4
Market Beating Performance
- The stock has generated a return of 90.06% in the last 1 year, much higher than market (S&P 500) returns of 29.58%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Interpace Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.22%
EBIT Growth (5y)
16.62%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.29%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
-7.47
EV to EBIT
1.63
EV to EBITDA
1.38
EV to Capital Employed
-7.45
EV to Sales
0.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
NET PROFIT(HY)
Higher at USD 23.57 MM
ROCE(HY)
Highest at 213.88%
RAW MATERIAL COST(Y)
Fallen by -2.17% (YoY
-13What is not working for the Company
NET SALES(HY)
At USD 18.26 MM has Grown at -23.7%
NET PROFIT(Q)
At USD 0.83 MM has Fallen at -86.63%
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.93 times
DEBT-EQUITY RATIO
(HY)
Highest at -6.79 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 12.52 times
Here's what is working for Interpace Biosciences, Inc.
Raw Material Cost
Fallen by -2.17% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Interpace Biosciences, Inc.
Net Profit
At USD 0.83 MM has Fallen at -86.63%
over average net sales of the previous four periods of USD 6.21 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Net Sales
At USD 18.26 MM has Grown at -23.7%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Debtors Turnover Ratio
Lowest at 4.93 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Debt-Equity Ratio
Highest at -6.79 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 12.52 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
